 Hans Dooms
Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Memory | 7 | 2021 | 313 | 1.570 |
Why?
| | Interleukin-2 | 12 | 2012 | 413 | 1.500 |
Why?
| | CD4-Positive T-Lymphocytes | 11 | 2021 | 960 | 1.360 |
Why?
| | Receptors, Interleukin-7 | 5 | 2017 | 25 | 1.270 |
Why?
| | Interleukin-7 | 6 | 2017 | 45 | 1.140 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 2021 | 337 | 1.060 |
Why?
| | Autoimmunity | 3 | 2021 | 815 | 1.010 |
Why?
| | Adoptive Transfer | 3 | 2021 | 194 | 0.850 |
Why?
| | Diabetes Mellitus, Type 1 | 6 | 2021 | 3254 | 0.830 |
Why?
| | STAT5 Transcription Factor | 2 | 2021 | 44 | 0.780 |
Why?
| | Lymphocyte Activation | 12 | 2021 | 1036 | 0.770 |
Why?
| | Antibodies, Monoclonal | 2 | 2019 | 1257 | 0.770 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 2 | 2018 | 26 | 0.730 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2018 | 193 | 0.730 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 11 | 0.640 |
Why?
| | T-Lymphocytes | 4 | 2013 | 1735 | 0.620 |
Why?
| | Adjuvants, Immunologic | 3 | 2007 | 206 | 0.600 |
Why?
| | Cytokines | 4 | 2023 | 1824 | 0.570 |
Why?
| | Scleroderma, Systemic | 1 | 2018 | 90 | 0.560 |
Why?
| | Lymphocytes | 2 | 2018 | 327 | 0.550 |
Why?
| | Receptors, Immunologic | 1 | 2018 | 198 | 0.550 |
Why?
| | Immunotherapy | 2 | 2019 | 473 | 0.550 |
Why?
| | Autoantigens | 2 | 2019 | 396 | 0.530 |
Why?
| | Islets of Langerhans | 1 | 2021 | 728 | 0.480 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2017 | 687 | 0.480 |
Why?
| | Interleukin-15 | 3 | 2012 | 74 | 0.420 |
Why?
| | T-Lymphocyte Subsets | 5 | 2018 | 383 | 0.390 |
Why?
| | Mice | 22 | 2023 | 14847 | 0.350 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 552 | 0.350 |
Why?
| | Autoimmune Diseases | 1 | 2013 | 381 | 0.340 |
Why?
| | Signal Transduction | 7 | 2021 | 4501 | 0.340 |
Why?
| | Animals | 26 | 2023 | 31570 | 0.320 |
Why?
| | Pneumonia, Pneumococcal | 2 | 2020 | 38 | 0.300 |
Why?
| | Cell Differentiation | 6 | 2020 | 1696 | 0.290 |
Why?
| | Antibodies, Blocking | 2 | 2018 | 32 | 0.260 |
Why?
| | Th2 Cells | 3 | 2023 | 154 | 0.250 |
Why?
| | Disease Models, Animal | 5 | 2020 | 3499 | 0.250 |
Why?
| | Leukocytes, Mononuclear | 2 | 2018 | 489 | 0.240 |
Why?
| | Immune Tolerance | 4 | 2013 | 321 | 0.230 |
Why?
| | Cell Proliferation | 5 | 2019 | 2173 | 0.220 |
Why?
| | Immunity | 2 | 2017 | 121 | 0.220 |
Why?
| | Helminthiasis | 1 | 2023 | 10 | 0.210 |
Why?
| | Cells, Cultured | 6 | 2017 | 3862 | 0.200 |
Why?
| | Apoptosis | 3 | 2000 | 2349 | 0.200 |
Why?
| | Mice, Inbred BALB C | 6 | 2010 | 1144 | 0.160 |
Why?
| | Immunization, Secondary | 1 | 1998 | 82 | 0.150 |
Why?
| | Mice, Transgenic | 6 | 2012 | 1947 | 0.150 |
Why?
| | Antigens, Viral | 1 | 1998 | 176 | 0.140 |
Why?
| | Immunity, Heterologous | 1 | 2017 | 2 | 0.140 |
Why?
| | Forkhead Transcription Factors | 3 | 2012 | 170 | 0.140 |
Why?
| | Antigens, CD | 2 | 2017 | 440 | 0.140 |
Why?
| | Homeostasis | 2 | 2013 | 570 | 0.140 |
Why?
| | Macrophages, Alveolar | 1 | 2020 | 348 | 0.140 |
Why?
| | Immunization | 1 | 2019 | 397 | 0.130 |
Why?
| | Receptors, Interleukin-2 | 2 | 2008 | 64 | 0.130 |
Why?
| | Cell Survival | 2 | 2013 | 1014 | 0.130 |
Why?
| | Mice, Knockout | 6 | 2010 | 2563 | 0.130 |
Why?
| | Streptococcus pneumoniae | 1 | 2017 | 133 | 0.130 |
Why?
| | Mitochondria | 2 | 2017 | 744 | 0.120 |
Why?
| | CD40 Ligand | 2 | 2012 | 37 | 0.120 |
Why?
| | Lipid Metabolism | 1 | 2017 | 441 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2012 | 615 | 0.120 |
Why?
| | Female | 10 | 2019 | 59349 | 0.110 |
Why?
| | Phenotype | 1 | 2021 | 2784 | 0.110 |
Why?
| | Th1 Cells | 3 | 2023 | 123 | 0.100 |
Why?
| | 4-1BB Ligand | 1 | 2012 | 6 | 0.100 |
Why?
| | Isoantigens | 1 | 2012 | 15 | 0.100 |
Why?
| | Humans | 14 | 2021 | 114080 | 0.100 |
Why?
| | Gene Expression Regulation | 4 | 2023 | 2322 | 0.100 |
Why?
| | Antigens, Differentiation | 1 | 2012 | 79 | 0.100 |
Why?
| | Energy Metabolism | 1 | 2017 | 727 | 0.100 |
Why?
| | Anemia, Hemolytic, Autoimmune | 2 | 2010 | 11 | 0.090 |
Why?
| | Vaccination | 1 | 2019 | 1202 | 0.090 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 2 | 2010 | 66 | 0.090 |
Why?
| | Mice, Inbred C57BL | 7 | 2017 | 4682 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2013 | 610 | 0.090 |
Why?
| | CD28 Antigens | 2 | 2007 | 47 | 0.080 |
Why?
| | Interferon-gamma | 1 | 2012 | 719 | 0.080 |
Why?
| | Lung | 2 | 2020 | 3521 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2090 | 0.060 |
Why?
| | Cell Separation | 2 | 2012 | 290 | 0.060 |
Why?
| | Oxygen Consumption | 2 | 2017 | 587 | 0.060 |
Why?
| | Mitomycin | 1 | 2004 | 27 | 0.060 |
Why?
| | Ovalbumin | 1 | 2004 | 161 | 0.060 |
Why?
| | Immunity, Innate | 2 | 2020 | 720 | 0.050 |
Why?
| | Cell Division | 1 | 2004 | 754 | 0.050 |
Why?
| | Clone Cells | 2 | 1998 | 247 | 0.050 |
Why?
| | Immunophenotyping | 2 | 1998 | 274 | 0.040 |
Why?
| | CD3 Complex | 1 | 2000 | 92 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2004 | 665 | 0.040 |
Why?
| | Cytochrome c Group | 1 | 2000 | 35 | 0.040 |
Why?
| | Aged | 1 | 2018 | 18973 | 0.040 |
Why?
| | Phosphatidylserines | 1 | 2000 | 87 | 0.040 |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | 1 | 1998 | 5 | 0.040 |
Why?
| | Neoplasms, Experimental | 1 | 1999 | 149 | 0.040 |
Why?
| | Chondroitin Sulfate Proteoglycans | 1 | 1998 | 9 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 126 | 0.040 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1998 | 84 | 0.040 |
Why?
| | Interphase | 1 | 1998 | 32 | 0.040 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1998 | 20 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 1998 | 132 | 0.040 |
Why?
| | Inflammation | 1 | 2008 | 2465 | 0.040 |
Why?
| | Middle Aged | 1 | 2018 | 26621 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1417 | 0.040 |
Why?
| | Oleic Acid | 1 | 2017 | 30 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 2017 | 139 | 0.040 |
Why?
| | Serogroup | 1 | 2017 | 27 | 0.040 |
Why?
| | Male | 2 | 2018 | 55420 | 0.040 |
Why?
| | Bacterial Load | 1 | 2017 | 58 | 0.030 |
Why?
| | DNA Replication | 1 | 1998 | 202 | 0.030 |
Why?
| | Cell Death | 1 | 1998 | 322 | 0.030 |
Why?
| | Adult | 1 | 2018 | 30395 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2017 | 104 | 0.030 |
Why?
| | Cellular Microenvironment | 1 | 2017 | 77 | 0.030 |
Why?
| | Extracellular Space | 1 | 2017 | 116 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2017 | 1128 | 0.030 |
Why?
| | Virulence | 1 | 2017 | 228 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2017 | 428 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1526 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2017 | 917 | 0.030 |
Why?
| | Metabolome | 1 | 2017 | 274 | 0.030 |
Why?
| | Proteins | 1 | 1999 | 906 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 1998 | 1144 | 0.030 |
Why?
| | Fibroblasts | 1 | 2017 | 836 | 0.030 |
Why?
| | Interleukin-15 Receptor alpha Subunit | 1 | 2012 | 1 | 0.030 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2012 | 18 | 0.030 |
Why?
| | RNA, Messenger | 1 | 1999 | 2550 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 180 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 511 | 0.020 |
Why?
| | Cyclosporine | 1 | 2012 | 161 | 0.020 |
Why?
| | Macrophages | 1 | 1998 | 1259 | 0.020 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2010 | 37 | 0.020 |
Why?
| | Graft vs Host Disease | 1 | 2012 | 212 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2010 | 198 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2010 | 170 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1469 | 0.020 |
Why?
| | Resting Phase, Cell Cycle | 1 | 2009 | 15 | 0.020 |
Why?
| | Vaccinia virus | 1 | 2009 | 27 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 356 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1075 | 0.020 |
Why?
| | Tumor Cells, Cultured | 2 | 1999 | 845 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2010 | 607 | 0.020 |
Why?
| | Skin | 1 | 2011 | 653 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3397 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2008 | 475 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 347 | 0.020 |
Why?
| | Antibodies | 1 | 2007 | 365 | 0.020 |
Why?
| | Phosphorylation | 1 | 2009 | 1559 | 0.020 |
Why?
| | Time Factors | 2 | 2009 | 6077 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2010 | 1016 | 0.010 |
Why?
| | Cell Line | 2 | 2000 | 2629 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2017 | 2087 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2003 | 136 | 0.010 |
Why?
| | Clonal Anergy | 1 | 2003 | 53 | 0.010 |
Why?
| | Staurosporine | 1 | 2000 | 21 | 0.010 |
Why?
| | Autoantibodies | 1 | 2007 | 1350 | 0.010 |
Why?
| | Growth Substances | 1 | 2000 | 138 | 0.010 |
Why?
| | fas Receptor | 1 | 2000 | 91 | 0.010 |
Why?
| | Etoposide | 1 | 2000 | 149 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2000 | 247 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2003 | 591 | 0.010 |
Why?
| | Versicans | 1 | 1998 | 5 | 0.010 |
Why?
| | Hemagglutinins | 1 | 1998 | 8 | 0.010 |
Why?
| | Injections, Intraperitoneal | 1 | 1998 | 99 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 1998 | 133 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 1998 | 150 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 863 | 0.010 |
Why?
| | Lymphoma | 1 | 1998 | 176 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1999 | 990 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1311 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1998 | 766 | 0.010 |
Why?
| | Biomarkers, Tumor | 1 | 1998 | 1032 | 0.010 |
Why?
|
|
Dooms's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|